The Latest Cardiac and Vascular News
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024. “I want to thank the Surmodics’ team for their extraordinary dedication and focus […]
SUNNYVALE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three and nine months ended September 30, 2024 by conference call on Wednesday, November 13, 2024 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
Brings over 30 years of experience in cardiovascular clinical research, business development, training, education, and medical affairs Strengthens Xeltis’ leadership team following IDE approval for initiation of US pivotal study for aXess™, its restorative vascular access conduit…
Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure Supports Licensing Partner’s Phase 3 Activities in Acute Heart Failure
– Collaboration leverages Ascendis’ proprietary TransCon™ technologies and Novo Nordisk’s expertise in cardiometabolic diseases
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass., Nov. 4, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire…
— Hospital Outpatient Prospective Payment System reimbursement rate doubled, expanding access to CCTA and supporting the technology’s superior accuracy and efficiency in cardiac care
BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided guidance.
Seasoned medical device executive to lead global commercial execution FREMONT, Calif., Oct. 31, 2024 /PRNewswire/ — Q’Apel Medical (Q’Apel), a private medical device company focused on revolutionizing neurovascular interventions, announced today the appointment of seasoned medical device…
CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today reported financial results for the third quarter ended September 30, 2024. GE HealthCare President and CEO Peter Arduini said, “In the third quarter, we reported sales and orders growth of 1% globally. Both sales and orders grew in the mid-single digits excluding China, with […]
